We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+21.57%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$734M
AUM Growth
+$11.9M
Cap. Flow
-$87.4M
Cap. Flow %
-11.9%
Top 10 Hldgs %
32.05%
Holding
98
New
33
Increased
14
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.8M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.6M
3
SNY icon
Sanofi
SNY
+$19.6M
4
WBA
Walgreens Boots Alliance
WBA
+$19M
5
TFX icon
Teleflex
TFX
+$15M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$34.4M
2
MCK icon
McKesson
MCK
+$21.7M
3
CYTK icon
Cytokinetics
CYTK
+$21.7M
4
AMGN icon
Amgen
AMGN
+$17.5M
5
CI icon
Cigna
CI
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.31%
2 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
CALL
Cytokinetics
CYTK
$10.7B
$33.4M 4.55%
+400,000
New +$14.5M
WBA
2
DELISTED
Walgreens Boots Alliance
WBA
$28.7M 3.91%
1,100,000
+850,000
+340% +$19M
THC icon
3
Tenet Healthcare
THC
$20.4B
$26.4M 3.6%
350,000
-190,000
-35% -$12M
ABBV icon
4
AbbVie
ABBV
$431B
$26.3M 3.59%
+170,000
New +$24.8M
NVS icon
5
Novartis
NVS
$291B
$22.7M 3.09%
225,000
+25,000
+13% +$2.41M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$78.3B
$22M 2.99%
+25,000
New +$20.6M
BSX icon
7
Boston Scientific
BSX
$71.1B
$21.7M 2.95%
375,000
-175,000
-32% -$9.34M
SNY icon
8
Sanofi
SNY
$102B
$19.9M 2.71%
+400,000
New +$19.6M
TFX icon
9
Teleflex
TFX
$6.2B
$17.5M 2.38%
+70,000
New +$15M
CYTK icon
10
Cytokinetics
CYTK
$10.7B
$16.7M 2.27%
200,000
-600,000
-75% -$21.7M
EHC icon
11
Encompass Health
EHC
$11B
$16.7M 2.27%
250,000
– –
LLY icon
12
Eli Lilly
LLY
$995B
$16.3M 2.22%
28,000
+3,000
+12% +$1.75M
DXCM icon
13
DexCom
DXCM
$32.8B
$15.5M 2.11%
125,000
-50,000
-29% -$5.11M
CRL icon
14
Charles River Laboratories
CRL
$11.3B
$15.4M 2.09%
+65,000
New +$12.8M
COR icon
15
Cencora
COR
$59.6B
$14.4M 1.96%
70,000
-40,000
-36% -$7.81M
NTRA icon
16
Natera
NTRA
$39.4B
$14.1M 1.92%
225,000
+25,000
+13% +$1.25M
ISRG icon
17
Intuitive Surgical
ISRG
$130B
$13.5M 1.84%
+40,000
New +$11.9M
MLTX icon
18
MoonLake Immunotherapeutics
MLTX
$1.53B
$13.3M 1.81%
220,000
-280,000
-56% -$14.4M
COO icon
19
Cooper Companies
COO
$14.6B
$13.2M 1.8%
140,000
+80,000
+133% +$6.71M
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$12.9M 1.76%
140,000
+90,000
+180% +$5.83M
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.5M 1.71%
175,000
+42,000
+32% +$2.42M
INSP icon
22
Inspire Medical Systems
INSP
$1.85B
$12.2M 1.66%
60,000
-45,000
-43% -$7.29M
ZBH icon
23
Zimmer Biomet
ZBH
$18.5B
$12.2M 1.66%
100,000
+30,000
+43% +$3.35M
NBIX icon
24
Neurocrine Biosciences
NBIX
$16.9B
$11.9M 1.62%
90,000
+5,000
+6% +$576K
CABA icon
25
Cabaletta Bio
CABA
$452M
$11.8M 1.61%
520,000
+190,000
+58% +$3.19M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Integral Health Asset Management held 98 positions worth $734M, up 1.7% from $722M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Integral Health Asset Management withdrew a net $87.4M in Q4 2023, closing 29 positions and reducing 20 holdings. Its most notable exit was argenx, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Integral Health Asset Management opened a new position in AbbVie worth $26.3M.

  • Integral Health Asset Management's largest Q4 2023 buy was AbbVie: 170,000 shares worth $26.3M.
  • Integral Health Asset Management added most to Walgreens Boots Alliance in Q4 2023, an estimated $19M increase.
  • Integral Health Asset Management's biggest Q4 2023 reduction was Cytokinetics, cutting an estimated $21.7M.
  • Integral Health Asset Management fully exited argenx in Q4 2023, selling an estimated $34.4M.
  • Integral Health Asset Management's ten largest holdings make up 32% of its $734M portfolio in Q4 2023.
  • Integral Health Asset Management opened 33 new positions and closed 29 in Q4 2023.
  • Integral Health Asset Management's portfolio value rose 1.7% quarter-over-quarter to $734M.

Based on Integral Health Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.